Fortress Biotech's stock jumped pre-market on September 5, 2025, driven by anticipation of its Menkes disease treatment approval.
- The surge reflects investor optimism ahead of the September 30 PDUFA date for regulatory decision-making.
- The biotech firm's focus on rare disease innovations has strengthened market confidence in its therapeutic pipeline.
https://www.ainvest.com/news/fortress-biotech-soars-13-73-menkes-disease-treatment-hopes-2509/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.